Helping your patient understand their treatment options is an important step towards choosing how you manage their MCL.
This is an overview of the patient pathway, from symptoms to potential treatments, which may be helpful for your patients who want to know what their journey may look like.
Although there is no standard of care for MCL, a range of treatment options are well established for patients.
Recently, there has been a shift in the treatment landscape in MCL to include the use of chemotherapy-free treatments with orally administered targeted agents in certain circumstances.
Unfortunately, despite the improvement in response durations with currently available therapies, patients will inevitably relapse.
Key symptoms your patients should be aware of include[^5]:
Your patients might be eager to know the cause of MCL, but while the cause is unknown, they can be made aware of the risk factors. These include
Diagnosis through a biopsy may be intimidating for patients, so it is important to reassure them that it is performed under general or local anaesthetics.
Your patients will want to know what treatments are available to them. It is important to make them aware that some treatment options are more intensive than others, and that treatment choice can depend on what type of MCL they have, their age and fitness, and quality of life considerations. The aim of treatment is to achieve a balance between efficacy outcomes and toxicity.
Patients will need to expect follow-up appointments after treatment to check their response to therapy, monitor their recovery and treat any delayed side effects.
MCL=mantle cell lymphoma.
This site has been developed by Janssen-Cilag International NV. Janssen-Cilag International NV is the responsible editor of this document
ITEM CODE: CP-233134 | DATE OF PREPARATION: June 2021